Caricamento...
An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
Acute myeloid leukemia (AML) is a major unmet medical need. Most patients have poor long-term survival, and treatment has not significantly changed in 40 years. Recently, bispecific antibodies that redirect the cytotoxic activity of effector T cells by binding to CD3, the signaling component of the...
Salvato in:
| Pubblicato in: | Blood |
|---|---|
| Autori principali: | , , , , , , , , , , , , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society of Hematology
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5290988/ https://ncbi.nlm.nih.gov/pubmed/27908880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-08-735365 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|